Vertex Pharmaceuticals Inc

“Vertex combines an elite cystic fibrosis franchise, very high profitability, strong cash generation, and a net-cash balance sheet, making it one of the best businesses in biotech. However, the investment case at the current market value depends too heavily on successful non-CF diversification that is strategically sensible but still not fully proven in realized earnings power. The business is strong enough to own, but the stock does not offer enough margin of safety for aggressive new buying.”